logo
6 "Bad" Foods that Could Actually Help Lower Blood Pressure, According to Dietitians

6 "Bad" Foods that Could Actually Help Lower Blood Pressure, According to Dietitians

Yahoo4 hours ago

Reviewed by Dietitian Kelli McGrane, M.S., RDDietitians love these six 'bad' foods because they contain nutrients important for blood pressure.
Baked potatoes, whole milk and orange juice contain potassium, which helps lower blood pressure.
Whole grain breakfast cereals, dark chocolate and coffee also offer benefits.There's conflicting messages around foods that are 'bad' for blood pressure, leaving you scratching your head trying to figure out which foods you should actually avoid. High blood pressure, or hypertension, is a condition where the force of blood against your artery walls is consistently too high. This pressure can put extra strain on your heart and lead to serious health issues over time. While managing high blood pressure isn't just about food, diet plays a crucial role in keeping it under control.
When it comes to food choices, some guidelines are more straightforward than others. For example, high sodium intake is known to increase blood pressure. However, some foods that get labeled as 'bad' for blood pressure may actually be perfectly fine—and even beneficial—to include in your diet. This article is here to flip the script on a few commonly misunderstood foods to show you that not all 'bad' foods are the villains they're made out to be when it comes to lowering blood pressure. Stick around and get ready to rethink your grocery list!
'Breakfast cereals can get a bad rap but it's time to rethink this pantry staple, especially for heart health,' says Karman Meyer, RDN. When made from whole grains and low in added sugar, breakfast cereal can be a helpful addition to a blood pressure-lowering diet. One study involving over 10,000 people found that those who ate more whole grains had a significantly lower chance of developing hypertension compared to those who ate less.
Meyer suggests looking for a cereal with at least 5 grams of fiber per serving, as there is a potential link between fiber intake and reduced blood pressure. You'll also want to do a quick scan of the ingredient list and look for a whole grain, like oats or 100% whole wheat flour, as the first ingredient. Another benefit of sitting down to a bowl of whole grain breakfast cereal in the morning? When enjoyed with milk, you get a boost of magnesium and calcium, both of which are important for reducing blood pressure, adds Meyer.
'One food often considered 'bad' that may actually support healthy blood pressure is dark chocolate. While it's sometimes seen as an indulgence, small amounts of dark chocolate (at least 70% cocoa) contain flavanols—plant compounds that help improve blood vessel function and increase nitric oxide, which relaxes blood vessels and can lower blood pressure,' says Lisa Young, PhD, RDN. One study looked at the effects of consuming 1 mg of chocolate per gram of body weight during periods of stress. The results showed that dark chocolate consumption was associated with a 10% reduction in diastolic blood pressure, while milk chocolate showed no significant benefit. For optimal health benefits, Young recommends sticking to 1 or 2 small squares (about ½ ounce) at a time to avoid excess sugar and calories.
Thanks to their high carb content, potatoes are often lumped into the 'limit' category. Baked potatoes in particular get a bad rap as they're often loaded with butter and cheese. While you may want to make some adjustments to your toppings, Colleen Wysocki, MS, RDN, CLC points out that baked potatoes contain a key nutrient for blood pressure management: potassium. 'Increasing potassium is just as important as decreasing sodium to lower blood pressure,' explains Wysocki. 'Potassium helps open up the blood vessels and supports the elimination of excess sodium in the urine. Both of these actions contribute to lower blood pressure,' she adds.
For folks with high blood pressure, the American Heart Association recommends consuming 3,500 mg to 5,000 mg of potassium daily. Baked potatoes can help make a serious dent in your potassium needs, with one medium baked potato providing 1,110 mg of potassium.
Before planning your next DIY baked potato bar, Wycoski offers some words of caution: 'It's important to keep in mind that a baked potato with added salt, butter, cheese or bacon [may] have high levels of sodium, and negate the benefits of the inherent potassium. Instead, consider a low-sodium plant-based spread, a dollop of sour cream or yogurt or olive oil with green onions to enhance the flavor'.
Drinking coffee gets a bad rap when it comes to blood pressure support because it contains caffeine—a stimulant known to temporarily raise blood pressure. This short-term effect happens because caffeine can cause the blood vessels to tighten, leading to a quick spike in pressure. On top of that, coffee's energizing effects are often associated with an increased heart rate, which makes some people wary about its impact on heart health.
However, it's not all bad news. In fact, the long-term effects of coffee are much more positive. Some data suggests that drinking coffee consistently and in moderation (about 1 to 3 cups per day) does not increase the risk of developing hypertension, and it may even offer protective benefits. For people who already have high blood pressure, regular moderate coffee consumption does not seem to worsen the condition or lead to uncontrolled blood pressure. It may even reduce the risk of death from other causes. Interestingly, it's occasional coffee drinkers who are more likely to experience a temporary spike in blood pressure.
Orange juice often gets a bad reputation because of its sugar content. While moderation is key, 100% orange juice (without added sugars) may actually be helpful for lowering blood pressure. Orange juice contains potassium and is an excellent source of vitamin C, both of which may help with blood pressure management.
Whole milk has been criticized for its saturated fat content. However, recent research suggests that whole milk may not be deserving of its 'bad' reputation. Turns out, dairy fat contains unique types of saturated fats that may not negatively affect heart health in the same way as other kinds of saturated fats, like those found in ultra processed foods, do. Further, studies examining whole fat dairy products haven't shown a link between full fat dairy consumption and worsening or increased risk of high blood pressure.
This is good news as whole milk is a great source of essential nutrients like calcium, potassium and magnesium—all of which are critical for maintaining healthy blood pressure levels and are emphasized on the Dietary Approaches to Stop Hypertension (DASH) diet. Plus, thanks to its higher fat content, whole milk may be more filling than low-fat or skim.
Exercise Regularly: Engaging in regular physical activity, such as walking, jogging or swimming, can help lower blood pressure by strengthening the heart and improving circulation. Aim for at least 30 minutes of moderate exercise most days of the week.
Reduce Sodium Intake: Limiting the amount of salt in your diet can significantly impact blood pressure levels.
Manage Stress: Chronic stress can contribute to elevated blood pressure. Practice relaxation techniques such as meditation, deep breathing or yoga to promote a sense of calm and reduce stress levels.
Limit Alcohol Consumption: Drinking alcohol in moderation, or not at all, can help maintain healthy blood pressure. For most adults, this means up to 1 drink per day for women and 2 for men.
Stay Properly Hydrated: Drinking enough water throughout the day may help regulate blood pressure by ensuring proper kidney function and supporting overall health.
The road to managing high blood pressure doesn't have to be paved with rigid restrictions and feared foods. Certain items often labeled as "bad," like dark chocolate, baked potatoes and whole milk, may actually be helpful additions to your plate. The key is making thoughtful, informed choices: look for fiber-rich cereals, enjoy a small square of dark chocolate with fruit or prepare baked potatoes with heart-friendly toppings.
At the end of the day, managing high blood pressure is about balance and understanding the holistic picture of your health. Maintaining a balanced diet, engaging in regular exercise, managing stress and staying hydrated are among key lifestyle habits for supporting healthy blood pressure levels.
Read the original article on EATINGWELL

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress
Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress

Yahoo

time16 minutes ago

  • Yahoo

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress

New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated in adults and adolescents with hemophilia A, with or without inhibitors1 FRONTIER5 Patient-Reported Outcomes assessment found the Mim8 pen-injector easy to use with strong user preference over their emicizumab injection system2 PLAINSBORO, N.J., June 22, 2025 /PRNewswire/ -- Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout period or Mim8 loading dose, was well tolerated in adults and adolescents living with hemophilia A, with or without inhibitors.1 Additionally, a FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use with an overall strong user preference for the pen-injector, in comparison to previous injection systems.2 The results were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C. "Continuous prophylactic coverage is critical to avoiding breakthrough bleeds in people living with hemophilia; with new non-factor therapeutic options, many people could have hesitations about switching treatment options. These data demonstrate that switching to Mim8 from emicizumab can be done without requiring a washout period," said Allison P. Wheeler, MD, Washington Center for Bleeding Disorders, Seattle, WA. "This is critical in ensuring that individuals maintain continuous protection against bleeding events as we seek to help address the ongoing needs of people living with this complex disease." In the open-label phase 3 FRONTIER5 safety study, 61 adults and adolescents aged 12 years and older with hemophilia A were enrolled.3 No thromboembolic events, hypersensitivity reactions, or treatment-emergent adverse events (TEAEs) leading to discontinuation were observed, and there was no evidence of neutralizing anti-Mim8 antibodies.1 Additional safety information from FRONTIER5 demonstrate that between Week 0 and Week 26 of treatment, there were 107 TEAEs observed in 43 patients (70.5%), most of which were mild to moderate (88.6%). There were 24 TEAEs that were possibly/probably related to Mim8 reported in 18 patients (29.5%). No thromboembolic events, hypersensitivity reactions, or TEAEs leading to discontinuation were observed.1 The PROs data from FRONTIER5 indicated overall (97%; n=57/59) patients preferred the Mim8 pen injection, with 97% of those patients reporting a "very strong" or "fairly strong" preference in comparison to their previous emicizumab injection system. Of the participants who completed the Hemophilia Device Handling and Preference Assessment (HDHPA) questionnaire at week 26, 98% (n=58/59) found the Mim8 pen-injector "very easy" or "easy" to use, and 95% (n=56/59) found it "much easier" or "easier" compared with their previous administration method. All participants (100%) were "extremely confident" or "very confident" in using the pen-injector correctly.2 "The FRONTIER5 safety and patient-reported outcomes data support Mim8 as a potential future treatment option for people living with hemophilia A and demonstrate our continued commitment to developing innovative treatment options for the hemophilia community," said Stephanie Seremetis, Chief Medical Officer and CVP for Rare Disease at Novo Nordisk. "These results give valuable insights into hemophilia A management, highlight the feasibility of directly switching to Mim8 from emicizumab, and reveal a strong patient preference for the Mim8 pen-injector device." Novo Nordisk aims to submit Mim8 for U.S. and EU regulatory review during 2025. Data from the ongoing phase 3 FRONTIER program will be disclosed at upcoming congresses and in publications in 2025 and 2026. About hemophiliaHemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.4 It is estimated to affect approximately 1,125,000 people worldwide.5 There are different types of hemophilia, which are characterized by the type of clotting factor protein that is defective or missing.4 Hemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and hemophilia B is caused by a missing or defective clotting Factor IX.4 Inhibitors are an immune system response to the clotting factors in replacement therapy. Currently, it is estimated that up to 30% of people living with severe hemophilia A have inhibitors that can cause replacement therapies to stop working.6 About Mim8Mim8 is an investigational FVIIIa mimetic bispecific antibody designed with the aim to deliver once-monthly, once-every-two-weeks, or once-weekly prophylaxis for people living with hemophilia A, with or without inhibitors.7,8 Administered under the skin, Mim8 bridges Factor IXa and Factor X. This action replaces FVIII function, which helps restore the body's thrombin generation capacity, helping blood to clot.7,9 The use of Mim8 in people living with hemophilia A is investigational and not approved by regulatory authorities or available anywhere in the world. About the FRONTIER5 trialFRONTIER5 is a single-arm, open-label, 26-week, phase 3b trial evaluating the safety of switching from previous emicizumab prophylaxis treatment directly to Mim8 prophylaxis treatment using the Mim8 pen-injector in adults and adolescents with hemophilia A, with or without inhibitors.1 The FRONTIER clinical program investigates Mim8 as a prophylaxis treatment for people with hemophilia A, with or without inhibitors. The phase 3 program includes FRONTIER1, FRONTIER2, FRONTIER3, FRONTIER4 and FRONTIER5.1,8,10-12 About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a U.S. presence spanning 40 years, Novo Nordisk U.S. is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D, and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Contacts for further information: Media: Liz Skrbkova (US)+1 609 917 0632NNIMediaTeam@ James-Brown (Global)+45 3079 9289Globalmedia@ Investors: Frederik Taylor Pitter (US) +1 609 613 0568fptr@ Martin Wiborg Rode (Global)+45 3075 5956jrde@ Meyer (Global) +45 3079 6656 azey@ Schaap Melvold (Global) +45 3077 5649 idmg@ Ung (Global)+45 3077 6414mxun@ References Oldenberg J, Benson G, Chowdaryet P, et al. FRONTIER5 direct switch study: safety of initiating Mim8 prophylaxis without washout of emicizumab. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2025; June 21-25 2025; Walter E. Washington Convention Center, Washington D.C., US. Session code 13686. Mahlangu J, Ahuja S, Cockrell E, et al. FRONTIER5 device handling and patient-reported outcomes. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2025; June 21–25 2025; Walter E. Washington Convention Center, Washington D.C., US. Session code 13786. A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER5). Last accessed May 2025. Available at MedlinePlus. Hemophilia. Last accessed May 2025. Available at Iorio A, Stonebraker JS, Chambost H, et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med. 2019;171:540-546. Kim JY, You CW. The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A. Blood Res. 2019;54:204-209. Ostergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138:1258-1268. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER4). Last accessed May 2025. Available at U.S. National Library of Medicine. F8 gene. MedlinePlus Genetics. Last accessed May 2025. Available at A Research Study Investigating Mim8 in People With Haemophilia A. Last accessed June 2025. Available at A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors. Last accessed May 2025. Available at A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors. Last accessed May 2025. Available at Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2025 Novo Nordisk All rights reserved. US25HRBD00174 June 2025 View original content to download multimedia: SOURCE Novo Nordisk Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

This Poop 'Cure' May Have Unintended Long-Term Effects, Study Finds
This Poop 'Cure' May Have Unintended Long-Term Effects, Study Finds

Yahoo

timean hour ago

  • Yahoo

This Poop 'Cure' May Have Unintended Long-Term Effects, Study Finds

Faecal microbial transplants (FMT), which involve transferring stool samples from a healthy gut to someone else's colon, have yielded some impressive medical results in the past. Researchers have seen promising signs of its ability to address irritable bowel syndrome, Crohn's disease, and even early Parkinson's (though this benefit only seemed to be short-lived) and other neurological issues. It has a 90% success rate for treating a bacterium related to diarrhoea, the BBC reported. But a new study published in the journal Cells has raised questions about the long-term safety of FMT treatments, suggesting that a bacterial 'mismatch' may cause problems with the patient's immune system and metabolism down the line. The scientists only found the link in mice and were not able to say how the changes they witnessed in the animals might manifest in people. They gave antibiotics to mice to interrupt their gut's normal microbiome, and then treated them with FMT and monitored them for one to three months. Often, the researchers discovered, the gut bacteria ended up in the wrong part of the gut – 'regional mismatches' – that seemed to disrupt the gut. After taking biopsies of the liver and gut, the scientists found that some genes, especially those related to the immune system and metabolism, had changed. Speaking to the University of Chicago, the study's lead author, researcher Orlando 'Landon' DeLeon said: 'I think it's a bit of a wake-up call to the field that maybe we shouldn't willy-nilly put large bowel microbes into different parts of the intestine that shouldn't be there. 'There are microbes along the entire intestinal tract, and we just study predominantly the last third of it (the colon),' he added. 'So how can you expect an FMT, with microbes from a third of the intestinal tract at the end of it, to fix the rest of the intestine?' No. This study was done on mice, which have different anatomies from us; even though the scientists found genetic changes in the liver and gut, they are not sure yet how those changes might affect even the mouse, never mind us. The study's researchers, however, still think it's a good idea to pursue 'omni-microbial transplants,' or OMT, writing in their paper: 'regional microbial mismatches after FMTs can lead to unintended consequences and require rethinking of microbiome-based interventions.' OMTs would include more bacteria from a greater area of the gut, theoretically increasing the likelihood that the correct ones will go to the right spot. Gut Health Discovery Could Help Future Parkinson's Diagnoses Let's Settle This – Is The Viral 'Puff Vs Pit' Armpit Health Check Actually Helpful? New Study Finds The Exact Age Bad Health Habits Catch Up To You

Can Behavioral Support Enhance CGM Use in T1D?
Can Behavioral Support Enhance CGM Use in T1D?

Medscape

timean hour ago

  • Medscape

Can Behavioral Support Enhance CGM Use in T1D?

TOPLINE: Behavioral support for first-time users of a continuous glucose monitoring (CGM) device showed no significant difference in reduction of A1c levels compared with CGM alone in the management of type 1 diabetes (T1D). Adults in both groups reported reduced diabetes distress. METHODOLOGY: Automated insulin delivery systems are the standard of care for adults with T1D, and using them requires both an insulin pump and a CGM device. A randomized controlled trial was conducted to assess the use of CGM among 134 adults with T1D who had not previously used CGM (mean age, 35 years; 77% women; 55% not using an insulin pump) who were recruited from clinics and T1D organizations across the United States. Participants were randomly assigned to one of two groups: one received CGM alone and the other received CGM plus the ONBOARD behavioral intervention, both for 3 months. The ONBOARD intervention included four 60-minute virtual, 1:1 biweekly sessions to address barriers related to wearing the device, data management, social concerns, and trust. Changes in A1c levels and diabetes distress scores were evaluated using t-tests and linear mixed-effect models over 12 months. TAKEAWAY: At 12 months after initiating CGM, 80% of participants in the ONBOARD group and 71% in the CGM-only group reported using CGM. Both the CGM-only and ONBOARD groups showed significant reductions in A1c levels (P < .05), with no significant difference between the groups. Participants in both groups experienced significant and clinically meaningful decreases in diabetes distress (P < .001). The CGM-only group showed greater reductions in diabetes distress than the ONBOARD group at 3 months; reductions were similar between groups at 6 and 12 months. IN PRACTICE: "Findings highlight benefits of introducing CGM on diabetes management and diabetes distress for adults with T1D. Most participants were still using CGM 12 months after initiating use through the study, indicating durable uptake," the authors write. SOURCE: The study was led by Molly L. Tanenbaum, PhD, Stanford University School of Medicine, California. The poster will be presented on June 23 at the American Diabetes Association (ADA) 85th Scientific Sessions, being held June 20-23 at the McCormick Place Convention Center, Chicago, Illinois. LIMITATIONS: No study limitations were discussed in the abstract. DISCLOSURES: One author disclosed consulting roles with Sanofi and Havas Health, an advisory role with MannKind Corporation, and receiving research support from embecta. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store